CEL-SCI Corporation (NYSE MKT: CVM) announced today that an interim review of
the safety data from its open label, randomized, controlled, pivotal Phase III
study of Multikine (Leukocyte Interleukin, Injection) investigational
immunotherapy by an...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.